Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Takashi Owa

Yoichi Ozawa

Taro Semba

Naoko Hata

Norihiro Ueda

Yasuhiro Funahashi

Akihiko Tsuruoka

Keiko Takahashi

Yuji Yamamoto

Tadashi Okabe

Toru Haneda

Kazumasa Nara

Junichi Kamata

Shinichi Hamaoka

Toshiaki Wakabayashi

Takeshi Nagasu

Nozomu Koyanagi

Kentaro Yoshimatsu

Hiroshi Yoshino

Kyosuke Kito

Noako Tsukahara

Tatsuo Okauchi

Naoko Sugi

Takayuki Hida

Norimasa Miyamoto

Takatoshi Kawai

Naoko Tsukahara

Hiroyuki Kato

Junro Kuromitsu

Akira Yokoi

The present invention relates to pharmaceutical compositions comprising a sulfonamide-including compound in combination with an angiogenesis inhibitor.

Use of sulfonamide-including compounds in combination with angiogenesis inhibitors

The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them, wherein in the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, &#x2014;CH&#x2550;CH&#x2014; or &#x2014;(CRR)&#x2014; (wherein Rand Rare the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and mmeans an integer of 1 or 2); Rmeans hydrogen atom or a C1-C6 alkyl group; Z means a single bond or &#x2014;CO&#x2014;NH&#x2014;; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.

Integrin expression inhibitor

Susceptibility of a tumor cell to an anticancer agent is tested by measuring an expression level or levels of a gene or genes selected from the group consisting of the genes listed in Tables 3 and 4 in a tumor cell collected from a cancer patient treated with an anticancer agent (E7070 and related compounds thereof), or causing the anticancer agent to act on a tumor cell collected from a cancer patient and measuring an expression level or levels of a gene or genes selected from the group consisting of the genes listed in Tables 3 and 4 in the tumor cell, and determining that the tumor cell is susceptible to the anticancer agent when the expression level or levels of the gene or genes listed in Table 3 increase, or the expression level or levels of the gene or genes listed in Table 4 decrease.

Method of testing anticancer agent-sensitivity of tumor cells

An appetite-stimulating agent and a therapeutic agent for anorexia, each comprising, as an active ingredient, a sulfonamide derivative or sulfonic acid ester derivative represented by the following general formula (I):

Appetite-stimulating agents and remedies for anorexia

Sulfonamide-containing heterocyclic compounds

Sulfonamide-containing indole compounds

Novel heterobicyclic sulfonamide and sulfonic ester derivatives represented by the following general formula (I), which exhibit an antitumor activity and are lowly toxic, and processes for the preparation thereof. A sulfonamide derivative and a sulfonic ester derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof: ##STR1## wherein variables A, W, X, B, C, Y, Z are as defined in the specification.

7-Amino-1H-indoles

Heterobicyclic sulfonamide and sulfonic ester derivatives

Growing community of inventors

Ibaraki, Japan

Takashi Owa